Continuous Glucose Monitoring (CGM) in 2025: A Practical, Cost-Conscious Prescribing Guide for Physicians

Executive summary

Continuous glucose monitoring (CGM) is now standard of care for many adults with diabetes, and 2025 brings clarifying guidance, simpler eligibility, and new device options. ADA Standards of Care 2025 support CGM across a broader clinical spectrum, while Medicare criteria now cover all insulin-treated patients and certain non-insulinpatients with documented problematic hypoglycemia. Recent device updates (e.g., Dexcom G7 “15-day” sensor clearance) further simplify use. A consistent, price-transparent workflow—compare costs, confirm coverage, e-prescribe—can reduce callbacks and improve adherence. Diabetes JournalsAmerican Diabetes AssociationAmerican Academy of Family PhysiciansCenters for Medicare & Medicaid ServicesDexCom Investors

1) Evidence & indications: who should be on CGM in 2025?

ADA 2025 recommends real-time (rtCGM) or intermittently scanned CGM (isCGM) to improve glycemic outcomes across age groups. The 2025 update also highlights CGM consideration for adults with type 2 diabetes on glucose-lowering agents beyond insulin when clinically appropriate. These recommendations reflect strong data for A1C reduction, hypoglycemia mitigation, and time-in-range improvements. Diabetes JournalsAmerican Diabetes Association

2) Coverage & access: what changed and how to operationalize it

Medicare: Coverage now includes (1) any insulin-treated beneficiary and (2) individuals with problematic hypoglycemia meeting documentation criteria, with the historical finger-stick requirement removed. Practically: document diagnosis, insulin use (if applicable), and/or specific hypoglycemia events; reference the local coverage article language in your note. American Academy of Family PhysiciansCenters for Medicare & Medicaid ServicesAmerican Diabetes Association

Commercial: Plans vary, but many mirror Medicare’s modernization. When insurance is prohibitive or delays care, offer transparent cash-pay options and let patients decide at the point of care. eNavvi’s platform is designed for side-by-side cash-price comparison and direct prescribing. enavvi.comformulary.enavvi.com

3) Device landscape & counseling pearls (2025)

• Dexcom G7 (including 15-day): In April 2025, FDA cleared Dexcom G7 15-day for adults (anticipated U.S. availability in the second half of 2025). Discuss wear duration, accuracy, app ecosystem, and compatibility with AID systems as updates roll out. DexCom InvestorsDexcom
• FreeStyle Libre 3: Ensure patients are on current lots; note prior 2024 sensor medical device correction affecting a small distribution window. Counsel on adhesive care and app usage. U.S. Food and Drug Administration
• Special situations: The FDA has acknowledged expanding device labeling related to imaging workflows for certain CGMs; verify current device instructions before CT/MRI to avoid interruptions. Verywell Health

Patient counseling quick-hits: alarm fatigue mitigation, how to act on trends vs. single readings, sick-day rules, and when to confirm with capillary testing.

4) Coding & documentation you’ll actually use

• Technical/Setup & Training: 95249 (personal CGM) or 95250 (professional CGM placement/training), typically once per 30 days as applicable.
• Interpretation/Report: 95251 (CGM analysis/interpretation/report).
• Remote monitoring (when used): pair with RPM codes per payer policy.
  Check your local payer policies for bundling/exclusions and POS rules. American Academy of Family Physiciansprovider.dexcom.com

5) A practical, point-of-care workflow (using eNavvi)

Search & compare: In eNavvi, look up CGM devices and compare cash prices vs likely coverage—so patients see their options up front. formulary.enavvi.com

Document eligibility: For Medicare, explicitly note insulin therapy or problematic hypoglycemia with qualifying events; for commercial plans, mirror criteria and include A1C/hypoglycemia history. Centers for Medicare & Medicaid Services

Counsel & consent: Review device specifics, app setup, data-sharing, and alert thresholds; set expectations for time-in-range goals. Diabetes Journals

E-prescribe: Send the device, sensors, and (if needed) reader via eNavvi for pickup or mail-order fulfillment to reduce friction and delays. enavvi.com

Follow-up: Schedule data review (2–4 weeks for initiation, then quarterly). Bill interpretation when appropriate (e.g., 95251). American Academy of Family Physicians

6) Safety alerts & special situations

• Lot-specific issues: Libre 3 had a limited 2024 sensor correction; advise patients to contact support if readings seem inconsistent or if sensor is from the impacted period. U.S. Food and Drug Administration
• Imaging: Confirm current labeling before CT/MRI; growing clearances reduce unnecessary removals but still verify per device. Verywell Health

Key takeaways

• ADA 2025 supports CGM broadly, with expanded consideration for adults with type 2 diabetes beyond insulin. Diabetes JournalsAmerican Diabetes Association
• Medicare covers all insulin users and certain non-insulin patients with problematic hypoglycemia; document specifically. American Academy of Family PhysiciansCenters for Medicare & Medicaid Services
• Dexcom G7 “15-day” clearance (adult) and other updates simplify device selection; stay current on rollout timing. DexCom InvestorsDexcom
• Use a price-transparent, digital workflow (compare → counsel → e-prescribe via eNavvi) to reduce friction and improve adherence.